Showing results (461-470 of 474) with videos related to

Sort By:
Pageof 48
Immunity|November 11, 2018
Inhibiting Inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ Transplant AcceptanceMounia S Braza, Mandy M T van Leent, Marnix Lameijer, et al.
The Journal of Infectious Diseases|July 20, 2021
Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since InfectionStéphane Pelleau, Tom Woudenberg, Jason Rosado, et al.
World Journal of Emergency Surgery : WJES|February 13, 2025
Indocyanine green fluorescence-guided surgery in the emergency setting: the WSES international consensus position paperBelinda De Simone, Fikri M Abu-Zidan, Luigi Boni, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 24, 2022
SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registryMaria Gonzalez-Cao, Teresa Puertolas, Clara Martinez-Vila, et al.
The Lancet. Oncology|June 5, 2019
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trialElisa A Rozeman, Alexander M Menzies, Alexander C J van Akkooi, et al.
Gut|March 6, 2026
Novel insights into autoimmune gastritis: clinical profile and gastric neoplastic risk from an international multicentre studyMarco Vincenzo Lenti, Emanuela Miceli, Irfan Soykan, et al.
The Lancet. Respiratory Medicine|August 14, 2018
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysisMichäel Duruisseaux, Anna Martínez-Cardús, Maria E Calleja-Cervantes, et al.
Nature Medicine|June 6, 2022
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trialIrene L M Reijers, Alexander M Menzies, Alexander C J van Akkooi, et al.
Nature Biotechnology|June 13, 2022
Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCRMegan Schwarz, Denis Torre, Daniel Lozano-Ojalvo, et al.
Nature Medicine|January 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trialLotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen, et al.
Pageof 48